AU2001265186A1 - Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions - Google Patents

Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions

Info

Publication number
AU2001265186A1
AU2001265186A1 AU2001265186A AU6518601A AU2001265186A1 AU 2001265186 A1 AU2001265186 A1 AU 2001265186A1 AU 2001265186 A AU2001265186 A AU 2001265186A AU 6518601 A AU6518601 A AU 6518601A AU 2001265186 A1 AU2001265186 A1 AU 2001265186A1
Authority
AU
Australia
Prior art keywords
treatment
epoxyeicosatrienoic acids
cerebrovascular conditions
cerebrovascular
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265186A
Inventor
James K. Liao
Michael A Moskowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
General Hospital Corp
Original Assignee
Brigham and Womens Hospital Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, General Hospital Corp filed Critical Brigham and Womens Hospital Inc
Publication of AU2001265186A1 publication Critical patent/AU2001265186A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001265186A 2000-05-30 2001-05-30 Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions Abandoned AU2001265186A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20797800P 2000-05-30 2000-05-30
US60/207,978 2000-05-30
PCT/US2001/017452 WO2001091745A2 (en) 2000-05-30 2001-05-30 Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions

Publications (1)

Publication Number Publication Date
AU2001265186A1 true AU2001265186A1 (en) 2001-12-11

Family

ID=22772743

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001265186A Abandoned AU2001265186A1 (en) 2000-05-30 2001-05-30 Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions

Country Status (3)

Country Link
US (1) US20020077355A1 (en)
AU (1) AU2001265186A1 (en)
WO (1) WO2001091745A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (en) 2001-08-02 2003-02-21 Suntory Ltd Composition having preventing and ameliorating action on symptom or disease caused by decrease in brain function
FR2843026B1 (en) * 2002-08-02 2006-01-06 Goemar Lab Sa NEW MEDICINE
JP4522075B2 (en) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 Composition having an effect of preventing or ameliorating symptoms or diseases caused by aging of blood vessels
EP1765311A4 (en) * 2004-03-16 2009-04-29 Univ California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
JP4993852B2 (en) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 Composition having a preventive or ameliorating effect on symptoms or diseases accompanied by behavioral abnormalities caused by stress
US8242170B2 (en) * 2005-06-06 2012-08-14 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
JP5967855B2 (en) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 Composition having an activity of reducing daytime activity and / or depressive symptoms
ATE555656T1 (en) * 2005-08-19 2012-05-15 Univ California USE OF VISION INHIBITORS AS ANALGESICS
CN101563088A (en) * 2006-12-18 2009-10-21 弗·哈夫曼-拉罗切有限公司 Novel use of inhibitors of soluble epoxide hydrolase
KR101430214B1 (en) 2006-12-28 2014-08-18 산토리 홀딩스 가부시키가이샤 Nerve regeneration agent
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US20160008342A1 (en) 2014-06-16 2016-01-14 The Regents Of The University Of California Methods of improving cell-based therapy
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916843B1 (en) * 1999-08-11 2005-07-12 The United States Of America As Represented By The Department Of Health And Human Services Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids

Also Published As

Publication number Publication date
US20020077355A1 (en) 2002-06-20
WO2001091745A2 (en) 2001-12-06
WO2001091745A3 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2002223599A1 (en) Pyrimidinone derivatives and their use in the treatment of atherosclerosis
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU2001234837A1 (en) Azapeptides useful in the treatment of hepatitis c
AU4439401A (en) Methods and apparatus usable with or applicable to the use of the internet
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
AU2003255993A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
AU2837301A (en) Use of polymeric material in the treatment of hard surfaces
AU2001260834A1 (en) The treatment of herpes
AU2002243363A1 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
AU5056099A (en) Compounds for use in the treatment of inflammation
AU5262200A (en) Arrangement in ventilatory treatment of the lungs
PT1152756E (en) USEFUL ANTICONVULSIVE DERIVATIVES IN THE TREATMENT OF AUTISM
AU2001236929A1 (en) Surface treatment
AU2003219511A1 (en) Carnitine in the treatment of geriatric depression
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU5565401A (en) Materials and methods for the treatment of depression
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2001280299A1 (en) Improvements in and relating to methods and apparatus for the application of honey to wounds
AU2002241162A1 (en) Intimins in the prevention or treatment of infections:ii